Global Overactive Bladder Therapeutics Market 2014-20180280035Overactive bladder (or overactive bladder syndrome) is a urological condition characterized by storage symptoms such as urgency, changes in the frequency of urination, nocturia, or incontinence. Although not a life-threatening condition, it is often debilitating and stigmatized. The pathophysiology of overactive bladder is not characterized completely. The symptoms can be lifelong or relapsing and remitting or it can be resolved. An overactive bladder can affect anyone irrespective of their gender. It is caused by the abnormal contraction of the detrusor muscles of the bladder. An overactive bladder can also be related to neurological diseases such as Parkinson's disease and multiple sclerosis.
Covered in this Report0280035This report covers the present scenario and the growth prospects of the Global Overactive Bladder Therapeutics market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various branded, generic, and off-label drugs used to treat overactive bladder, which include: Antimuscarinic agents
Beta-3 adrenergic receptor agonists
View our full TOC hereKey Regions
Astellas Pharma Inc.
Other Prominent Vendors
American Oriental Bioengineering
Ion Channel Innovations
Kwang Dong Pharmaceutical
LG Life Sciences
Taris BioMedicalTeva Pharmaceutical
Please join StudyMode to read the full document